Cesca Therapeutics (NASDAQ:KOOL) issued its quarterly earnings results on Tuesday. The biotechnology company reported ($0.47) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.60) by $0.13, Bloomberg Earnings reports. Cesca Therapeutics had a negative return on equity of 51.45% and a negative net margin of 355.50%. The company had revenue of $4.31 million during the quarter, compared to analysts’ expectations of $3.40 million.

KOOL traded down $0.31 on Wednesday, reaching $2.69. 509 shares of the stock were exchanged, compared to its average volume of 66,457. The firm’s 50-day moving average is $3.07. The stock has a market capitalization of $7.90 million, a price-to-earnings ratio of -0.78 and a beta of 1.00. Cesca Therapeutics has a fifty-two week low of $2.10 and a fifty-two week high of $5.25. The company has a quick ratio of 0.81, a current ratio of 1.58 and a debt-to-equity ratio of 0.54.

A number of analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $6.50 price target (up previously from $1.00) on shares of Cesca Therapeutics in a research report on Wednesday. ValuEngine raised Cesca Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, July 2nd.

Cesca Therapeutics Company Profile

Cesca Therapeutics Inc develops, commercializes, and markets a range of automated technologies and products for cell-based therapeutics in the United States, China, rest of Asia, Europe, and internationally. The company develops automated blood and bone marrow processing systems that enable the separation, processing, and preservation of cell and tissue therapy products.

Featured Story: Why is Cost of Capital Important?

Earnings History for Cesca Therapeutics (NASDAQ:KOOL)

Receive News & Ratings for Cesca Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cesca Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.